Cortexyme, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 8.95%147.960.0%$976.95m
AMGNAmgen, Inc. 0.70%254.811.5%$857.91m
GILDGilead Sciences, Inc. -0.11%64.401.0%$544.24m
VRTXVertex Pharmaceuticals, Inc. 1.04%272.451.9%$492.78m
REGNRegeneron Pharmaceuticals, Inc. 0.78%688.782.6%$437.93m
ILMNIllumina, Inc. 5.06%255.893.3%$329.32m
NVAXNovavax, Inc. 18.93%55.9875.7%$307.36m
BIIBBiogen, Inc. 0.46%205.151.8%$233.76m
BNTXBioNTech SE 4.92%165.930.0%$221.36m
SNSSSunesis Pharmaceuticals, Inc. 2.86%2.160.7%$150.99m
EXASEXACT Sciences Corp. 6.46%53.0817.7%$136.48m
TXG10X Genomics, Inc. 11.94%53.010.0%$106.48m
TECHBio-Techne Corp. 5.45%385.244.5%$105.78m
BMRNBioMarin Pharmaceutical, Inc. 2.35%80.714.2%$96.76m
CRSPCRISPR Therapeutics AG 4.20%57.550.6%$83.77m

Company Profile

Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.